C Michael Gibson/Baim Institute
Feb 16, 2026, 06:21
C. Michael Gibson: Favorable Safety Outcomes With Asundexian
C. Michael Gibson, President and CEO at Baim Institute for Clinical Research, Professor of Medicine at Harvard Medical School, and Executive Board Member at EXCITE International, shared a post on LinkedIn:
”No increase in any type of bleeding with Asundexian. Even minor bleeding was not increased (was numerically lower).”
Stay updated with Hemostasis Today.
-
Jul 9, 2026, 19:20Bradley Maron: The Beginning of a New Chapter for Circulation
-
Jul 9, 2026, 19:00Wolfgang Miesbach: ISTH 2026 Showcases the Future of Gene Therapy
-
Jul 9, 2026, 18:21Martin Vanden Eede: Can We Safely Reduce Anticoagulation During ECMO?
-
Jul 9, 2026, 18:00Dorothée Faille: Discovering Versailles During ISTH 2026
-
Jul 9, 2026, 16:45Rutbaa Ayaz Shaikh: One Step Further in Medical Research
-
Jul 9, 2026, 14:49Celebrating a Century of von Willebrand Disease Research and Care – Seminars in Thrombosis and Hemostasis
-
Jul 9, 2026, 14:38Valance Washington: International Hemostasis Community Prepares for GRC 2026
-
Jul 9, 2026, 14:27Dima Shulkin: Next-Generation AI Models Improve Early Sepsis Recognition
-
Jul 9, 2026, 14:12Omar Hajji: Seasonal Determinants of Mortality in Sepsis and Cardiogenic Shock